Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 4Recurrence 2Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Hematologic Diseases 1Disease Progression 1Disease 1Blood Protein Disorders 1

Interventions

fluciclovine F-18 2Positron-Emission Tomography 2Injections 2Dexamethasone 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2tislelizumab 1technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1ricolinostat 1pomalidomide 1pembrolizumab 1lortalamine 1gossypol acetic acid 1daratumumab 1aflibercept 1Prednisone 1Oncolytic Virotherapy 1Octreotide 1Mitomycin 1Mammography 1Lenalidomide 1Ipilimumab 1Drug Delivery Systems 1Docetaxel 1Diagnosis, Computer-Assisted 1Daunorubicin 1Cytarabine 1Control Groups 1CPX-351 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Disease × ricolinostat × Clear all
NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1 Completed
16 enrolled
Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡